Category: Uncategorized

  • Fisetin

    Plain-language summaryIntrigue 78 / 100

    Fisetin is a natural flavonoid found in strawberries and apples that selectively kills senescent cells (a senolytic). Mayo Clinic researchers identified it in screens looking for natural compounds with senolytic activity. Clinical trials are ongoing. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Flavonol polyphenol with senolytic, anti-inflammatory, and neuroprotective activity

    A naturally occurring 3,7,3′,4′-tetrahydroxyflavone identified as one of the most potent flavonoid senolytics, with convergent activity across PI3K/Akt/mTOR inhibition, SIRT1 activation, NF-kappaB suppression, and Nrf2-mediated antioxidant defense, positioned at the intersection of aging biology, neurodegeneration, and cancer chemoprevention research.

    Abstract

    Fisetin (3,7,3′,4′-tetrahydroxyflavone) is a bioactive flavonol found at highest dietary concentration in strawberries and at lower levels in apples, persimmons, grapes, onions, and cucumbers. First isolated from the heartwood of Venetian sumac (Cotinus coggygria) in the late nineteenth century and characterized as a plant pigment, fisetin remained a minor flavonoid of limited pharmacological interest until convergent twenty-first-century discoveries established it as a multi-target agent active across the principal molecular pathways of cellular senescence, neurodegeneration, inflammation, and oncogenesis. The compound was identified as a potent senolytic in the landmark Zhu et al. (2017) screen at the Mayo Clinic Robert and Arlene Kogod Center on Aging, and the subsequent Yousefzadeh et al. (2018) demonstration that late-life oral fisetin administration extended median and maximum lifespan in wild-type mice while reducing senescence-associated markers in multiple tissues positioned it as the leading dietary flavonoid candidate for translational senolytic therapy [1, 2]. Mechanistically, fisetin operates through a convergent multi-pathway pharmacology: it inhibits PI3K/Akt/mTOR signaling by direct suppression of PI3K catalytic and regulatory subunit expression and by activation of the mTOR repressor TSC2 through concurrent AMPK phosphorylation; it activates SIRT1-dependent deacetylation cascades that suppress NF-kappaB transcriptional activity and the senescence-associated secretory phenotype (SASP); it induces Nrf2 nuclear translocation and downstream phase II antioxidant enzyme expression; and it modulates the Bcl-2 family balance toward pro-apoptotic signaling selectively in senescent cells [3, 4, 5]. The neuroprotective profile has been extensively characterized by the Maher laboratory at the Salk Institute for Biological Studies, where fisetin and its optimized derivative CMS121 have demonstrated efficacy in transgenic Alzheimer’s disease mouse models through reduction of lipid peroxidation via fatty acid synthase (FASN) inhibition, suppression of neuroinflammatory cascades, and maintenance of glutathione homeostasis [6, 7]. CMS121 completed a Phase 1 clinical trial in 2025, with single doses up to 1800 mg and repeat doses up to 900 mg per day for 7 days demonstrating acceptable tolerability and favorable pharmacokinetic parameters in healthy volunteers [8]. The anticancer pharmacology spans preclinical efficacy in prostate, breast, colorectal, lung, melanoma, pancreatic, and bladder cancer models, principally through cell cycle arrest at G2/M and G1/S checkpoints, mitochondrial apoptosis induction, and suppression of epithelial-mesenchymal transition and matrix metalloproteinase expression [9, 10]. Clinical translation is constrained by the poor oral bioavailability characteristic of hydroxylated flavonols: fisetin undergoes rapid and extensive phase II conjugation (glucuronidation and sulfation) in the intestinal epithelium and liver, producing low systemic free flavonol concentrations after oral dosing; multiple formulation strategies (nanocochleates, liposomes, nanoemulsions, hybrid hydrogels) have demonstrated 10- to 140-fold bioavailability enhancement in preclinical and early human pharmacokinetic studies [11, 12]. Clinical trials led by the Kirkland laboratory at Mayo Clinic are evaluating fisetin at oral doses of 20 mg/kg per day for senolytic indications including frailty in aging (AFFINITY trial, NCT03675724), COVID-19 in skilled nursing facilities, and sepsis in elderly patients (STOP-Sepsis, NCT05758246) [13, 14]. This monograph reviews the chemistry, natural sourcing, and structural pharmacology of fisetin; the multi-pathway molecular mechanism across senescence, inflammation, neuroprotection, and oncogenesis; the pharmacokinetic limitations and formulation solutions; the preclinical evidence base across aging, neurodegeneration, and cancer; the clinical trial landscape; sourcing and quality verification for research applications; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five senolytic or flavonoid candidates against fisetin on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1481Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Boswellic-Acid

    Pentacyclic triterpenic acid from Boswellia serrata oleogum resin with selective 5-lipoxygenase inhibition and pleiotropic anti-inflammatory activity

    A family of ursane- and oleanane-type pentacyclic triterpenes isolated from Boswellia serrata frankincense resin, distinguished by noncompetitive allosteric inhibition of 5-lipoxygenase and convergent anti-inflammatory activity through NF-kappaB suppression, topoisomerase inhibition, and leukotriene biosynthesis blockade.

    Abstract

    Boswellic acids are a family of pentacyclic triterpenic acids isolated from the oleogum resin (frankincense) of Boswellia serrata and related species (B. carterii, B. sacra, B. papyrifera) that have been used in Ayurvedic medicine for centuries under the name Salai guggal and are now recognized as pharmacologically active anti-inflammatory agents with a distinct mechanism of action centered on selective, noncompetitive, allosteric inhibition of 5-lipoxygenase (5-LOX). The family comprises four principal bioactive congeners: beta-boswellic acid (beta-BA), 11-keto-beta-boswellic acid (KBA), 3-O-acetyl-beta-boswellic acid (ABA), and 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), with AKBA representing the most potent 5-LOX inhibitor (IC50 approximately 1.5 micromolar in human neutrophils) and the primary pharmacologically characterized congener. The 5-LOX inhibition by AKBA proceeds through an allosteric, nonredox, noncompetitive mechanism that is unique among clinically studied leukotriene synthesis inhibitors and distinguishes the boswellic acid class from both the redox-type 5-LOX inhibitors (zileuton) and the competitive cysteinyl leukotriene receptor antagonists (montelukast, zafirlukast). Beyond 5-LOX inhibition, boswellic acids exert convergent anti-inflammatory activity through suppression of NF-kappaB signaling via direct inhibition of IkappaB kinases (IKKalpha and IKKbeta), inhibition of human leukocyte elastase, inhibition of topoisomerases I and IIalpha, modulation of complement system activation, and suppression of proinflammatory cytokine release including tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6. Pharmacokinetics in humans are characterized by poor oral bioavailability of the keto-boswellic acids (KBA and AKBA) attributable to extensive first-pass hepatic metabolism via CYP3A4-mediated hydroxylation and carboxylesterase 2-mediated deacetylation, with plasma elimination half-lives of approximately 6 hours. Concomitant administration with a lipid-rich meal substantially improves absorption. Clinical evidence from randomized controlled trials supports efficacy in osteoarthritis (pain reduction and functional improvement at 100 to 250 mg AKBA-enriched extract daily), bronchial asthma (improvement in 70 percent of patients at 300 mg three times daily), inflammatory bowel disease (Crohn’s disease and ulcerative colitis, with response rates comparable to mesalazine), and radiation-induced cerebral edema (greater than 75 percent edema reduction in 60 percent of patients at 4200 mg daily). The compound class is generally well tolerated, with the principal adverse events being mild gastrointestinal discomfort (nausea, acid reflux, diarrhea) and rare allergic dermatitis. This monograph reviews the chemistry, structural pharmacology, and biosynthesis of the boswellic acid family; the multi-target mechanism of action in molecular detail; the comprehensive human pharmacokinetic record including bioavailability enhancement strategies; the clinical evidence base across osteoarthritis, asthma, inflammatory bowel disease, cerebral edema, and oncology-supportive indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five alternative anti-inflammatory natural compounds against boswellic acids on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1495Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pirenzepine

    Selective M1 muscarinic acetylcholine receptor antagonist of the pyridobenzodiazepinone structural class

    A peripherally selective, M1-preferring muscarinic antagonist developed at Dr. Karl Thomae GmbH (Boehringer Ingelheim) as a gastric antisecretory agent for peptic ulcer disease, subsequently investigated as a topical ophthalmic intervention for the retardation of progressive myopia in children.

    Abstract

    Pirenzepine (LS 519, Gastrozepin) is a tricyclic pyridobenzodiazepinone and the prototypical selective antagonist of the M1 subtype of the muscarinic acetylcholine receptor. Synthesized at Dr. Karl Thomae GmbH, a subsidiary of Boehringer Ingelheim, in the mid-1970s, the compound was the first muscarinic antagonist demonstrated to discriminate pharmacologically between what were subsequently classified as M1 and M2 receptor subtypes, a finding reported by Hammer et al. in 1980 in Nature and foundational to the modern subtype classification of muscarinic receptors [1]. Pirenzepine binds the M1 muscarinic receptor with a dissociation constant (Ki) of approximately 5 to 14 nanomolar and displays 5- to 20-fold selectivity over the M2, M3, and M5 subtypes, with intermediate affinity at M4 receptors [2, 3]. The compound is peripherally selective, exhibiting negligible penetration of the blood-brain barrier at therapeutic oral doses, a property that minimizes central anticholinergic adverse effects and distinguishes it from atropine and other non-selective muscarinic antagonists. The primary registered indication is peptic ulcer disease. Pirenzepine inhibits vagally mediated and pentagastrin-stimulated gastric acid secretion through antagonism of M1 receptors on intramural gastric plexus neurons, reducing basal acid output by approximately 50 percent at oral doses of 50 mg twice daily [4, 5]. Extensive controlled trials conducted through the late 1970s and 1980s demonstrated duodenal ulcer healing rates of 60 to 76 percent at 4 to 8 weeks on pirenzepine 100 to 150 mg per day, broadly comparable to cimetidine 1 g per day and superior to placebo and gefarnate [6, 7]. The compound was registered as Gastrozepin in numerous European, Asian, and Latin American jurisdictions but was never approved by the United States Food and Drug Administration. The clinical importance of pirenzepine as a gastric antisecretory agent has diminished substantially following the introduction of histamine H2 receptor antagonists and proton pump inhibitors, which offer superior acid suppression and ulcer healing rates. A second, more recent research application is the retardation of progressive myopia (axial elongation of the globe) in children aged 8 to 12 years. Two multicenter, randomized, double-masked, placebo-controlled trials of 2% pirenzepine ophthalmic gel, conducted by Siatkowski et al. (2004, 2008), demonstrated approximately 50 percent reduction in the rate of myopia progression over 1- and 2-year treatment periods, with a clinically acceptable safety profile dominated by mild pupil dilation and accommodation difficulty [8, 9]. The mechanism of the antimyopic effect is incompletely characterized but is attributed to M1 and possibly M4 muscarinic receptor antagonism in the retina and sclera, modulating signaling cascades that regulate scleral extracellular matrix remodeling and axial elongation [10]. The ophthalmic application has not received regulatory approval; the compound remains investigational for myopia control, with atropine (a non-selective muscarinic antagonist applied at low concentrations) having advanced further in clinical development for this indication. Pharmacokinetics are characterized by low oral bioavailability (20 to 30 percent in fasted subjects, further reduced by food), a plasma elimination half-life of approximately 10 to 12 hours, negligible hepatic first-pass metabolism, predominant renal elimination of unchanged drug, and low plasma protein binding (approximately 12 percent) [11, 12]. The compound does not undergo significant cytochrome P450-mediated metabolism and has a correspondingly limited drug-drug interaction profile. The principal adverse events at registered oral doses are mild anticholinergic effects: dry mouth (approximately 14 percent), blurred vision (1 to 5 percent, dose-dependent), and constipation (approximately 3 percent), with an overall discontinuation rate of approximately 2 percent in controlled trials [6]. Serious adverse events are rare. This monograph reviews the chemistry, synthesis, and structural pharmacology of pirenzepine; the molecular pharmacology at muscarinic receptor subtypes; comprehensive human pharmacokinetics; the clinical evidence base across peptic ulcer and myopia indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five gastric antisecretory and muscarinic antagonist alternatives (telenzepine, atropine, cimetidine, ranitidine, omeprazole) against pirenzepine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1459Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Apigenin

    Trihydroxyflavone with multi-target activity spanning CD38 NADase inhibition, GABA-A receptor modulation, aromatase suppression, and broad anti-inflammatory and pro-apoptotic signaling

    A dietary flavone abundant in chamomile, parsley, and celery, distinguished from other common flavonoids by potent CD38 NADase inhibition with consequent elevation of intracellular NAD+, moderate GABA-A receptor activity at the benzodiazepine site, competitive aromatase inhibition, and a broad preclinical pharmacology spanning anti-inflammatory, neuroprotective, anti-cancer, and metabolic endpoints.

    Abstract

    Apigenin (4′,5,7-trihydroxyflavone) is a naturally occurring flavone present at high concentration in chamomile flowers, parsley, celery, and numerous other dietary plant sources. It is one of the most extensively studied plant flavonoids, with a preclinical research literature encompassing anti-inflammatory, antioxidant, neuroprotective, anxiolytic, anti-cancer, cardioprotective, and metabolic activities. The compound is distinguished from the structurally related flavonoids quercetin, luteolin, and kaempferol by several pharmacological features of particular current research interest: potent inhibition of CD38, the principal mammalian NAD+-degrading ectoenzyme, resulting in elevation of intracellular nicotinamide adenine dinucleotide (NAD+) and consequent activation of sirtuin-dependent deacetylation pathways relevant to metabolic syndrome and aging; moderate activity at the benzodiazepine binding site of the gamma-aminobutyric acid type A (GABA-A) receptor, producing anxiolytic and sedative effects in rodent models; competitive inhibition of aromatase (CYP19A1) with an IC50 of approximately 20 to 23 micromolar, reducing estrogen biosynthesis; and suppression of NF-kappaB-driven proinflammatory cytokine production through multiple converging mechanisms including direct IKK-beta inhibition and modulation of the PI3K/AKT and MAPK/ERK signaling cascades.

    The CD38 inhibitory activity, formally characterized by Escande et al. (2013) in a report from the Bhatt, Chini, and Sinclair laboratories, demonstrated that apigenin administration to obese mice increased tissue NAD+ levels, decreased global protein acetylation through sirtuin activation, and improved glucose and lipid homeostasis parameters [1]. This finding positioned apigenin within the NAD+ restoration research framework alongside nicotinamide mononucleotide and nicotinamide riboside, though through a mechanistically distinct pathway (reduced NAD+ degradation rather than precursor supplementation). The GABA-A receptor activity, first reported by Viola et al. (1995) using competitive radioligand displacement at the benzodiazepine site, produced anxiolytic effects in elevated plus maze and open field paradigms in mice without the sedation, amnesia, or muscle relaxation characteristic of classical benzodiazepines [2]. Subsequent electrophysiological and behavioral studies have produced conflicting characterizations of the precise nature of the GABA-A interaction, with reports variously describing apigenin as a weak partial agonist, an antagonist, or an inverse agonist at the benzodiazepine site depending on assay system and concentration.

    Pharmacokinetics in humans are incompletely characterized. Oral bioavailability is estimated at approximately 30 percent, limited by poor aqueous solubility and extensive first-pass phase II conjugation (glucuronidation and sulfation). Phase I oxidative metabolism is mediated principally by CYP1A1, CYP1A2, and CYP2E1, producing the hydroxylated metabolite luteolin as the major oxidative product. The plasma elimination half-life after oral administration is approximately 2 to 3 hours in the limited human pharmacokinetic data available. Apigenin inhibits CYP2C9, CYP3A4, and P-glycoprotein in vitro at concentrations that may be clinically relevant at supplemental doses, raising drug-drug interaction considerations.

    The compound is non-mutagenic and non-genotoxic in standard regulatory toxicology assays. No significant toxicity has been observed in animal studies at doses up to 50 mg/kg, though hepatotoxicity has been reported at intraperitoneal doses of 100 mg/kg and above in mice. Human safety data at supplemental doses (50 to 500 mg daily) are limited but have not produced serious adverse event signals. The principal reported adverse effects at supplemental doses are drowsiness (consistent with GABA-A activity) and mild gastrointestinal discomfort.

    This monograph reviews the chemistry, natural sources, and isolation history of apigenin; the multi-target molecular pharmacology spanning CD38, GABA-A, aromatase, and inflammatory signaling; the available pharmacokinetic data in animals and humans; the preclinical pharmacology across neuroprotective, anti-cancer, anti-inflammatory, and metabolic endpoints; the limited clinical evidence base; sourcing and quality verification for research applications; reconstitution and handling; stack interactions; adverse events and safety; and a comparative assessment of five structurally or functionally related flavonoid compounds against apigenin on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1484Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Dihydro-NMN

    Reduced pyridine nucleotide and potent NAD+ precursor of the dihydronicotinamide mononucleotide class

    A reduced-form nicotinamide mononucleotide that bypasses canonical salvage pathway enzymes to elevate cellular NAD+ and NADH more rapidly and to a greater extent than its oxidized counterpart NMN, with emerging preclinical evidence in renal cytoprotection, metabolic reprogramming, and anti-proliferative activity.

    Abstract

    Dihydronicotinamide mononucleotide (NMNH), also designated reduced nicotinamide mononucleotide or dihydro-NMN, is the 1,4-dihydropyridine analog of beta-nicotinamide mononucleotide (NMN). The compound differs from NMN by a single additional hydrogen at the C-4 position of the nicotinamide ring, converting the aromatic pyridinium to a non-aromatic 1,4-dihydropyridine and conferring distinct biochemical, pharmacokinetic, and pharmacological properties. NMNH was first characterized as a potent nicotinamide adenine dinucleotide (NAD+) precursor in mammalian systems in two independent 2021 reports: Zapata-Perez et al. in The FASEB Journal demonstrated that NMNH increases NAD+ levels to a substantially greater extent and faster than NMN or nicotinamide riboside (NR) across multiple tissues in mice, while Liu et al. in the Journal of Proteome Research showed that NMNH potently enhances NAD+ and NADH, suppresses glycolysis and the tricarboxylic acid cycle, induces reductive stress, and inhibits cell growth in hepatocellular carcinoma cells. The metabolic pathway of NMNH is mechanistically distinct from that of NMN: NMNH is converted directly to NADH by nicotinamide mononucleotide adenylyltransferase (NMNAT) without requiring nicotinamide phosphoribosyltransferase (NAMPT) or nicotinamide riboside kinase (NRK), the two rate-limiting enzymes of the canonical salvage and Preiss-Handler pathways. The resulting NADH is then oxidized to NAD+ by cellular oxidoreductases, producing a net elevation of both reduced and oxidized pyridine dinucleotide pools. In vivo, intraperitoneal administration of NMNH to mice elevates hepatic NAD+ approximately five-fold and renal NAD+ approximately two-fold, with significant increases also observed in brain, skeletal muscle, brown adipose tissue, and heart, tissues in which equivalent doses of NMN produce no statistically significant NAD+ elevation. The Zapata-Perez et al. study additionally demonstrated that NMNH protects conditionally immortalized proximal tubular epithelial cells against hypoxia and reoxygenation injury, reducing expression of the kidney injury biomarker Kim-1 and the mitochondrial dysfunction marker Tfam, establishing a preclinical basis for renal cytoprotection. The Liu et al. metabolomic analysis revealed that NMNH-treated cells exhibit marked suppression of glycolytic intermediates (glucose-6-phosphate, fructose-1,6-bisphosphate, phosphoenolpyruvate, pyruvate) and tricarboxylic acid cycle intermediates (citrate, alpha-ketoglutarate, succinate, fumarate, malate), accompanied by cell cycle arrest and growth inhibition. The compound induces cellular reductive stress through elevation of the NADH/NAD+ ratio, which paradoxically increases reactive oxygen species (ROS) production, linking the reductive stress phenotype to the anti-proliferative activity. NMNH is prepared by chemical reduction of NMN with thiourea dioxide in alkaline aqueous solution or by enzymatic cleavage of NADH with NADH pyrophosphatase (NudC). The compound is supplied as the disodium salt (CAS 108347-85-9) and is commercially available from multiple research chemical suppliers. A first-in-human clinical trial reported in January 2026 indicated that oral NMNH at 500 mg daily for 90 days approximately tripled circulating NAD+ levels in healthy adults, though these results remain unpublished and unverified by independent peer review. No regulatory approval exists for NMNH in any jurisdiction; the compound is sold as a dietary supplement or research reagent. This monograph reviews the chemistry, synthesis, and structural distinction from NMN; the NMNAT-dependent metabolic pathway; the preclinical pharmacology across NAD+ elevation, renal cytoprotection, metabolic reprogramming, and anti-proliferative activity; the limited pharmacokinetic data in mice and humans; the emerging clinical evidence; sourcing and quality verification; reconstitution and handling; stack interactions with other NAD+ precursors and metabolic modulators; the adverse-event and safety signal including reductive stress and reactive oxygen species concerns; and a comparative assessment of five NAD+ precursor candidates against NMNH on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1486Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Solriamfetol

    Plain-language summaryIntrigue 68 / 100

    Solriamfetol, sold as Sunosi, is a wakefulness-promoting medication FDA-approved in 2019 for daytime sleepiness in narcolepsy and obstructive sleep apnea. It is a selective dopamine and norepinephrine reuptake inhibitor with clean pharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Selective dopamine and norepinephrine reuptake inhibitor (DNRI) with trace amine-associated receptor 1 (TAAR1) agonist activity

    A phenylalanine-derived dual dopamine-norepinephrine reuptake inhibitor developed by SK Biopharmaceuticals and commercialized by Jazz Pharmaceuticals as the first DNRI approved for the treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea.

    Abstract

    Solriamfetol (JZP-110, SKL-N05, ADX-N05) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) approved in the United States (March 2019) and the European Union (January 2020) for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnea (OSA). Chemically derived from the amino acid D-phenylalanine, solriamfetol is the (R)-enantiomer of 2-amino-3-phenylpropyl carbamate and is supplied as the hydrochloride salt for oral administration. The compound inhibits the reuptake of dopamine (IC50 approximately 2.9 micromolar) and norepinephrine (IC50 approximately 4.4 micromolar) at their respective plasma membrane transporters (DAT and NET) with minimal activity at the serotonin transporter. In addition, solriamfetol acts as an agonist at the human trace amine-associated receptor 1 (TAAR1) with an EC50 of approximately 10 to 16 micromolar, a concentration range overlapping its DAT and NET inhibitory potencies and achieved at clinically relevant plasma levels. Critically, the compound does not promote monoamine release, distinguishing it mechanistically from amphetamine and its analogs and supporting its classification as a reuptake inhibitor rather than a releasing agent. The clinical development program comprised five pivotal trials (TONES 1 through TONES 5). The Phase 3 TONES 2 trial in 231 narcolepsy patients demonstrated that solriamfetol at 150 mg and 300 mg once daily produced statistically significant improvements in the Maintenance of Wakefulness Test (MWT) mean sleep latency (increases of 9.8 and 12.3 minutes, respectively, versus 2.1 minutes for placebo at 12 weeks) and in the Epworth Sleepiness Scale (ESS). The Phase 3 TONES 3 trial in 459 OSA patients demonstrated similar dose-dependent improvements at 37.5, 75, 150, and 300 mg doses. The long-term TONES 5 open-label extension in 643 participants confirmed maintenance of efficacy and tolerability over 52 weeks. A randomized withdrawal phase within TONES 5 demonstrated that participants switched to placebo experienced a return of sleepiness (ESS worsening of 5.3 points versus 1.6 points for those continuing solriamfetol), confirming sustained pharmacological activity rather than natural remission. Pharmacokinetics are notable for high oral bioavailability (approximately 95 percent), minimal hepatic metabolism (less than 1 percent of dose recovered as the sole inactive metabolite N-acetyl solriamfetol), and predominant renal elimination of unchanged drug through active tubular secretion. The elimination half-life is approximately 7.1 hours in subjects with normal renal function. Because metabolism is negligible, solriamfetol carries essentially no cytochrome P450 drug interaction liability. However, renal impairment substantially prolongs elimination (half-life increased approximately 1.2-, 1.9-, and 3.9-fold in mild, moderate, and severe renal impairment, respectively), requiring dose adjustment in moderate and severe renal impairment and avoidance in end-stage renal disease. The principal adverse events are headache, nausea, decreased appetite, insomnia, and anxiety. Solriamfetol produces small, dose-dependent increases in systolic blood pressure (0.5 to 2.5 mmHg), diastolic blood pressure, and heart rate (0.7 to 2.9 beats per minute), consistent with its noradrenergic mechanism. Concurrent use with monoamine oxidase inhibitors is contraindicated. The compound is designated Schedule IV in the United States, reflecting low but measurable abuse potential at supratherapeutic doses. This monograph reviews the chemistry, synthesis, and stereochemistry of solriamfetol; the dual-transporter and TAAR1 pharmacology; the comprehensive pharmacokinetic profile; the clinical evidence base across narcolepsy and OSA indications; the sourcing and quality verification considerations for research applications; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five wake-promoting agents against solriamfetol on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1441Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pitolisant

    Plain-language summaryIntrigue 76 / 100

    Pitolisant, sold as Wakix, is a wakefulness-promoting medication that works through histamine receptors rather than dopamine. By blocking the H3 histamine autoreceptor (which normally puts a brake on histamine release), it increases brain histamine. FDA-approved for narcolepsy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Histamine H3 receptor inverse agonist/antagonist with secondary sigma-1 receptor agonism and wake-promoting eugeroic activity

    A first-in-class non-imidazole piperidine derivative developed at Bioprojet as a selective histamine H3 receptor inverse agonist, approved for narcolepsy-associated excessive daytime sleepiness and cataplexy, and distinguished from conventional stimulants by histaminergic wake promotion without dopaminergic reinforcement or controlled-substance classification.

    Abstract

    Pitolisant (BF2.649, Wakix) is the first histamine H3 receptor inverse agonist/antagonist to achieve regulatory approval, authorized by the European Medicines Agency in March 2016 and by the United States Food and Drug Administration in August 2019 for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The compound is a non-imidazole piperidine derivative, chemically designated 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride, that binds the human histamine H3 receptor with sub-nanomolar affinity (Ki approximately 0.3 to 1.0 nM) and functions as a potent inverse agonist at the constitutively active receptor with an EC50 of approximately 1.5 nM [1, 2]. By antagonizing presynaptic H3 autoreceptors on tuberomamillary histaminergic neurons, pitolisant enhances endogenous histamine synthesis and release, thereby activating downstream wake-promoting circuitry including noradrenergic, dopaminergic, and cholinergic projection systems, without direct dopaminergic reinforcement in the nucleus accumbens [3, 4]. This mechanistic distinction from amphetamine, modafinil, and solriamfetol is the pharmacological basis for the compound’s classification as a non-controlled substance in both the United States and the European Union, a clinically meaningful regulatory differentiation in a therapeutic area historically dominated by Schedule II and Schedule IV agents. The clinical evidence base for pitolisant in narcolepsy rests on the HARMONY trial program: HARMONY 1 demonstrated statistically significant reduction in Epworth Sleepiness Scale scores versus placebo (Cohen’s d 0.61) and significant reduction in weekly cataplexy rate (62% versus 8% for placebo) [5, 6]; HARMONY CTP confirmed anti-cataplectic efficacy with a Cohen’s d of 0.86 and a 75% reduction in weekly cataplexy rate versus 38% for placebo [7]; and HARMONY III established long-term safety and efficacy over 12 months of continuous dosing [8]. The FDA subsequently expanded the indication to include cataplexy in adults with narcolepsy (October 2020) and both excessive daytime sleepiness and cataplexy in pediatric patients aged 6 years and older (2024 and February 2026, respectively) [9]. Beyond narcolepsy, the HAROSA trial program has demonstrated efficacy for residual excessive daytime sleepiness in obstructive sleep apnea, with statistically significant ESS reductions at both 20 mg and 40 mg doses [10, 11]. Exploratory clinical and preclinical investigations extend to epilepsy, Prader-Willi syndrome, Parkinson’s disease-associated sleepiness, cognitive impairment, and obesity. Pharmacokinetics are characterized by high oral bioavailability (approximately 90%), rapid absorption with peak plasma concentrations at approximately 3 hours, plasma protein binding of 91 to 96%, and hepatic metabolism primarily via CYP2D6 and secondarily via CYP3A4, producing inactive metabolites conjugated with glycine or glucuronic acid [12]. The elimination half-life is 10 to 12 hours in most published pharmacokinetic analyses, though some reports note a range extending to 20 hours depending on the analytical methodology and population studied. CYP2D6 poor metabolizers exhibit approximately 2.4-fold increases in area under the curve, necessitating dose adjustment to a maximum of 17.8 mg daily in this population. The compound is well tolerated at approved doses of 8.9 to 35.6 mg daily; the principal adverse events are headache, insomnia, and nausea, with dose-dependent incidence [13]. QT interval prolongation is identified in the prescribing label, and the compound should be used with caution in patients with known QT prolongation or concurrent QT-prolonging medications. This monograph reviews the chemistry, synthesis, receptor pharmacology, pharmacokinetics, preclinical pharmacology, clinical evidence base across all studied indications, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five alternative wake-promoting or histamine-modulating agents against pitolisant on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1442Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • TB-500 Fragment

    Synthetic heptapeptide fragment of thymosin beta-4 encompassing the actin-binding domain (residues 17-23) with N-terminal acetylation

    A synthetic N-acetylated heptapeptide (Ac-LKKTETQ) derived from the central actin-binding domain of thymosin beta-4, investigated for tissue repair, angiogenesis, anti-inflammatory activity, and wound healing through modulation of actin polymerization dynamics and cellular migration.

    Abstract

    TB-500 Fragment (Ac-LKKTETQ) is a synthetic heptapeptide corresponding to residues 17 through 23 of the endogenous 43-amino acid polypeptide thymosin beta-4, a ubiquitous intracellular G-actin sequestering protein that participates in cytoskeletal organization, cell migration, angiogenesis, and tissue repair. The fragment encompasses the central actin-binding domain of the parent molecule and is N-terminally acetylated to confer resistance to aminopeptidase degradation and to replicate the post-translational modification present on native thymosin beta-4. TB-500 Fragment has been the subject of substantial preclinical investigation since the early 2000s, when Philp et al. (2003) demonstrated that the synthetic LKKTETQ heptapeptide promoted dermal wound repair in db/db diabetic mice and in aged mice at efficacy levels comparable to the full-length thymosin beta-4 molecule, establishing the actin-binding domain as a sufficient pharmacophore for the tissue repair activity of the parent protein. The principal molecular mechanism of TB-500 Fragment is sequestration of G-actin monomers and modulation of actin polymerization dynamics, which promotes cell migration, endothelial tube formation, keratinocyte mobilization, and extracellular matrix remodeling. Downstream signaling involves activation of integrin-linked kinase (ILK), phosphorylation of Akt/protein kinase B, suppression of NF-kappaB-mediated proinflammatory cytokine release, and upregulation of matrix metalloproteinases that facilitate tissue remodeling during wound repair. The pharmacological profile of TB-500 Fragment is therefore characterized by four principal activities: promotion of angiogenesis, acceleration of wound healing, anti-inflammatory modulation, and facilitation of stem and progenitor cell migration. Preclinical evidence in rodent models has demonstrated accelerated dermal wound closure in diabetic and aged animals, cardioprotection following experimental myocardial infarction (demonstrated with the parent thymosin beta-4 molecule in the landmark Bock-Marquette et al. 2004 Nature study), promotion of hair follicle stem cell activation and hair growth (Philp et al. 2004), and anti-inflammatory activity through suppression of NF-kappaB nuclear translocation and reduction of TNF-alpha and IL-1-beta production. Human clinical data for the heptapeptide fragment itself are limited; the majority of clinical evidence derives from the full-length thymosin beta-4 molecule, which has been evaluated in Phase 2 and Phase 3 clinical trials for dry eye disease (RGN-259, RegeneRx Biopharmaceuticals) and in Phase 2 studies for neurotrophic keratopathy. The Phase 2 dry eye trial demonstrated statistically significant improvements in ocular discomfort (35.1 percent reduction) and corneal fluorescein staining (59.1 percent reduction) relative to vehicle control. The Phase 3 ARISE program in dry eye disease did not meet co-primary endpoints, though statistically significant improvement in ocular grittiness was observed. TB-500 Fragment is not approved by any regulatory authority for human therapeutic use. It is classified as a prohibited substance by the World Anti-Doping Agency under Sections S0 (Non-Approved Substances) and S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) and is prohibited in equine racing competition by multiple national racing authorities. Pharmacokinetic data from preclinical studies indicate a plasma elimination half-life of approximately 1.5 to 3 hours following subcutaneous administration, with subcutaneous bioavailability of approximately 60 to 80 percent relative to intravenous dosing; tissue-level effects persist substantially longer than plasma residence, consistent with the intracellular mechanism of action. The compound is supplied as a lyophilized powder and is reconstituted in bacteriostatic water for injection; it is stable at refrigerated conditions for up to 30 days after reconstitution. This monograph reviews the chemistry, synthesis, and structural characterization of TB-500 Fragment; the molecular pharmacology of actin sequestration, ILK activation, and NF-kappaB suppression; the pharmacokinetic profile; the preclinical evidence base across wound healing, cardiac repair, hair growth, and anti-inflammatory models; the clinical evidence derived from the parent thymosin beta-4 molecule; sourcing and quality verification; reconstitution and handling; stack interaction considerations; adverse event and safety signal assessment; and a comparative evaluation of five alternative tissue repair and regenerative peptides against TB-500 Fragment on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1451Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Piracetam

    Plain-language summaryIntrigue 65 / 100

    Piracetam is the original racetam, synthesized in 1964 and the prototype of the entire nootropic concept. It was developed at UCB Pharma and is approved in many countries for cognitive impairment. It is the lowest-potency racetam with minimal side effects, often used as a starting point for racetam research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    2-Oxopyrrolidine acetamide nootropic and positive allosteric modulator of AMPA-type glutamate receptors

    A cyclic GABA derivative synthesized at UCB Pharma as the prototype nootropic agent, distinguished by positive allosteric modulation of AMPA receptors, restoration of membrane fluidity under hypoxic and aging conditions, inhibition of platelet aggregation, and a six-decade clinical record spanning cortical myoclonus, age-related cognitive decline, and acute ischemic stroke.

    Abstract

    Piracetam (2-oxo-1-pyrrolidineacetamide), the founding member of the racetam class and the first compound for which the term “nootropic” was coined, is a cyclic derivative of gamma-aminobutyric acid (GABA) that lacks direct GABAergic receptor activity and instead exerts its principal pharmacological effects through positive allosteric modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptors, restoration of neuronal membrane fluidity, inhibition of voltage-gated N-type calcium channels, and rheological modification of erythrocyte and platelet function. Synthesized in 1964 by Corneliu Giurgea at the Belgian pharmaceutical company UCB under the development code UCB 6215, piracetam was initially investigated as a GABA-related sedative-hypnotic but was rapidly recognized to possess a pharmacological profile fundamentally distinct from GABA agonism: it enhanced learning and memory in animal models without producing sedation, anxiolysis, or anticonvulsant activity at therapeutic doses, and it exhibited an exceptionally favorable safety profile with no identified lethal dose in standard rodent toxicology. Giurgea formalized this novel pharmacological category in 1972 by coining the term “nootropic” from the Greek nous (mind) and trepein (to bend), establishing criteria that included enhancement of learning and memory, protection of the brain against physical or chemical injury, enhancement of cortical and subcortical control mechanisms, and absence of the pharmacological profile of typical psychotropic drugs. The molecular pharmacology of piracetam centers on a weak but functionally relevant positive allosteric modulation of AMPA receptors, characterized crystallographically by Ahmed and Oswald (2010) as binding at a novel site along the AMPA receptor dimer interface distinct from the aniracetam and cyclothiazide binding sites [1]. At concentrations achieved by standard oral dosing (approximately 100 micromolar in cerebrospinal fluid after a 1200 mg oral dose), piracetam enhances AMPA receptor-mediated calcium influx, reduces receptor desensitization, and facilitates glutamatergic neurotransmission in cortical and hippocampal circuits. A second major mechanism is the restoration of membrane fluidity in aged, hypoxic, or otherwise compromised neuronal membranes through direct interaction with the phospholipid bilayer headgroup region, improving the mobility and function of membrane-embedded receptors and ion channels [2]. A third mechanism, inhibition of voltage-gated N-type calcium channels at low micromolar concentrations (IC50 approximately 3 micromolar in rat cortical neurons), contributes to neuroprotective activity under ischemic conditions [3]. Pharmacokinetics are characterized by near-complete oral absorption (bioavailability approaching 100 percent), absence of hepatic metabolism (no metabolites have been identified in any species), renal excretion of the unchanged compound accounting for greater than 98 percent of the administered dose, and a plasma elimination half-life of approximately 5 hours in adults with normal renal function [4, 5]. The cerebrospinal fluid half-life is approximately 8 hours, consistent with the sustained central nervous system activity observed clinically. The pharmacokinetic profile is uncomplicated by cytochrome P450 interactions, protein binding effects, or hepatic disease sensitivity; the sole clinically relevant pharmacokinetic modifier is renal function, with dose adjustment required in renal impairment and the half-life extending to approximately 59 hours in anuric end-stage renal disease. The clinical evidence base spans six decades and multiple indications. The strongest evidence supports the use of piracetam in cortical myoclonus, where it is approved in the United Kingdom and several European jurisdictions at high doses (7.2 to 24 grams per day) as adjunctive therapy, with randomized controlled trial evidence demonstrating significant improvement in motor disability, functional capacity, and global assessment scores [6, 7]. A second major clinical application is age-related cognitive decline and dementia, where a 2002 meta-analysis of 19 double-blind placebo-controlled trials by Waegemans et al. reported a global effect favoring piracetam across a heterogeneous population of older patients with cognitive impairment [8], while a 2012 Cochrane systematic review by Flicker and Grimley Evans concluded that the evidence was suggestive but insufficient to support routine clinical use in dementia [9]. A more recent 2024 systematic review and meta-analysis by Fang et al. of 18 studies and 886 patients reported mixed findings, with some measures of cognitive function showing benefit but overall memory outcomes failing to reach clinical significance [10]. A third clinical application, acute ischemic stroke, was studied in the Piracetam in Acute Stroke Study (PASS), a multicenter randomized trial of 927 patients receiving 12 grams intravenously within 12 hours of stroke onset, which did not demonstrate significant benefit on the primary endpoint but showed a signal of efficacy in the subgroup treated within 7 hours [11, 12]. The compound is well tolerated. The principal safety considerations are dose-dependent inhibition of platelet aggregation with prolongation of bleeding time at high doses (a class effect that warrants caution in patients with hemorrhagic risk factors, concurrent anticoagulant therapy, or pre-surgical status), and the requirement for gradual dose tapering in myoclonus patients to avoid withdrawal-related seizure exacerbation [13]. Common adverse events are mild and include nervousness, hyperkinesia, somnolence, and weight gain, with no organ toxicity identified in chronic dosing studies extending to years of treatment. The compound is not approved by the United States Food and Drug Administration and is classified as a dietary supplement ingredient or research compound in the United States; it is a registered prescription medicine in over 60 jurisdictions worldwide. This monograph reviews the chemistry, synthesis, and structural class of piracetam; the molecular pharmacology at AMPA receptors, neuronal membranes, and calcium channels; the comprehensive pharmacokinetic record; the clinical evidence base across myoclonus, cognitive impairment, stroke, and additional indications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signals; and a comparative assessment of five racetam-class alternatives against piracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1425Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Alpha-GPC

    Plain-language summaryIntrigue 64 / 100

    Alpha-GPC is a phospholipid that delivers choline to the brain efficiently. It supports acetylcholine production and is one of the more bioavailable choline supplements. Used in nootropic stacks alongside racetams to prevent the headaches some users experience from racetam-induced choline depletion. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Phospholipid-derived cholinergic precursor and acetylcholine biosynthetic substrate

    A high-bioavailability choline donor derived from phosphatidylcholine hydrolysis, developed in Italy as a prescription cholinergic agent for cognitive impairment and cerebrovascular disease, distinguished from other choline sources by efficient blood-brain barrier penetration and dual contribution of choline for acetylcholine synthesis and glycerophosphate for membrane phospholipid remodeling.

    Abstract

    Alpha-GPC (L-alpha-glycerylphosphorylcholine; choline alfoscerate; sn-glycero-3-phosphocholine; CAS 28319-77-9; molecular formula C8H20NO6P; molecular weight 257.22 g/mol) is an endogenous phospholipid intermediate in the deacylation pathway of membrane phosphatidylcholine and an exogenous cholinergic precursor that delivers bioavailable choline across the blood-brain barrier more efficiently than choline salts, choline bitartrate, or lecithin. The compound contains approximately 40 percent choline by mass, is freely water-soluble, highly hygroscopic, and is metabolized by phosphodiesterases in the intestinal mucosa and in central and peripheral tissues to yield free choline and glycerol-3-phosphate. The released choline serves as the immediate biosynthetic substrate for choline acetyltransferase-catalyzed acetylcholine synthesis in cholinergic neurons, while the glycerophosphate moiety enters the Kennedy pathway for phosphatidylcholine resynthesis, providing simultaneous support for neurotransmitter production and neuronal membrane integrity.

    Alpha-GPC was first synthesized by Baer and Kates in 1948 and entered pharmaceutical development in Italy in the 1980s under the trade names Gliatilin and Delecit. It is registered as a prescription medicine in Italy, Russia, and several Eastern European and Asian jurisdictions for the treatment of cognitive impairment associated with Alzheimer disease, cerebrovascular disease, and post-stroke cognitive decline. In the United States it is classified as a dietary supplement and is not regulated as a drug. The compound has accumulated a substantial clinical evidence base across multiple indications: a 2044-patient Italian multicenter trial in acute cerebrovascular disease (Barbagallo Sangiorgi et al. 1994); the De Jesus Moreno (2003) 261-patient multicenter randomized double-blind placebo-controlled trial demonstrating significant improvement on the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Mini-Mental State Examination (MMSE), and Global Deterioration Scale (GDS) at 1200 mg/day for 180 days in mild-to-moderate Alzheimer dementia; multiple open-label and controlled studies of combination therapy with acetylcholinesterase inhibitors; and recent systematic reviews and meta-analyses (Sagaro et al. 2023) confirming efficacy in adult-onset cognitive dysfunction with pooled effect sizes favoring alpha-GPC over placebo and over citicoline in head-to-head comparisons. Additional research applications include augmentation of growth hormone secretion during resistance exercise (Ziegenfuss et al. 2008), enhancement of peak force production in trained athletes, and investigation of motivational and attentional endpoints in healthy volunteers.

    Pharmacokinetics are characterized by rapid oral absorption with peak plasma choline elevation at approximately 1 to 2 hours, a choline elevation half-life of 4 to 8 hours, oral bioavailability exceeding 40 percent for choline delivery, and metabolism through phosphodiesterase-mediated hydrolysis rather than cytochrome P450-dependent pathways. The compound distributes widely, with particular concentration in brain, liver, and kidney. Excretion is predominantly renal as polar choline metabolites and expired carbon dioxide from betaine oxidation.

    The safety profile at registered doses (400 to 1200 mg/day) is favorable; the most commonly reported adverse events are mild gastrointestinal disturbance (nausea, heartburn, diarrhea), headache, and insomnia, occurring at rates modestly above placebo. A 2021 Korean retrospective cohort study (Lee et al. 2021) raised a signal for increased stroke risk with long-term alpha-GPC use, a finding that requires replication and mechanistic investigation. The proposed mechanism involves conversion of choline to trimethylamine by gut microbiota, hepatic oxidation to trimethylamine N-oxide (TMAO), and TMAO-mediated promotion of atherosclerosis and thrombosis. This signal has not been confirmed in prospective controlled trials and does not apply to short-term or moderate-dose use.

    This monograph documents the chemistry, synthesis, and preparation of alpha-GPC; the cholinergic precursor mechanism and downstream pharmacology; comprehensive pharmacokinetics; the clinical evidence base across cognitive, cerebrovascular, sport-performance, and adjunctive indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; the adverse-event and safety signal; and a structured comparative assessment of five alternative choline donors and cholinergic precursors (citicoline, choline bitartrate, phosphatidylcholine, DMAE, and centrophenoxine) against alpha-GPC on five standards: bioavailability, effect size, clinical validation, side-effect profile, and overall utility.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1443Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.